Salmonella Typhi Haplotype 58 (H58) Biofilm Formation and Genetic Variation in Typhoid Fever Patients with Gallstones in an Endemic Setting in Kenya

- 3 Peter Muturi^{a,b}, Peter Wachira^b, Maina Wagacha^b, Cecilia Mbae^a, Susan Kavai^a, Michael Mugo^a,
- 4 Musa Muhammed^c, Juan F. González^d, Samuel Kariuki^{a,e,f}#, John S. Gunn^{d,g}#
- 5 ^aCentre for Microbiology Research, Kenya Medical Research Institute
- 6 ^bDepartment of Biology, University of Nairobi, Kenya
- 7 ^cMinistry of Health, Kenya
- 8 ^dCenter for Microbial Pathogenesis, Abigail Wexner Research Institute at Nationwide Children's
- 9 Hospital, Columbus, OH, USA
- 10 ^eWellcome Sanger Institute, Cambridge, United Kingdom
- ¹¹ ^fDrugs for Neglected Diseases initiative Eastern Africa, Nairobi, Kenya
- ¹² ^gInfectious Diseases Institute, The Ohio State University, Columbus, OH, USA

13 14

15 **Running title**: *S*. Typhi genetic variation in asymptomatic carriers

16

- 17 #Co-Corresponding authors:
- 18 Samuel Kariuki, Ph.D.
- 19 Email: <u>samkariuki2@gmail.com</u>
- 20
- 21 John S. Gunn, Ph.D.
- 22 Email: John.Gunn@nationwidechildrens.org
- 23
- 24
- T
- 25
 - J
- 26
- 27
- 28
- 29
- 30

- -
- 32
- 33

34 Abstract

35 The causative agent of typhoid fever, Salmonella enterica serovar Typhi, is a human restricted pathogen. Human carriers, 90% of whom have gallstones in their gallbladder, continue to shed the 36 pathogen after treatment. The genetic mechanisms involved in establishing the carrier state are 37 poorly understood, but S. Typhi is thought to undergo specific genetic changes within the 38 gallbladder as an adaptive mechanism. In the current study, we aimed to identify biofilm forming 39 ability and the genetic differences in longitudinal clinical S. Typhi isolates from asymptomatic 40 carriers with gallstones in Nairobi, Kenya. Whole genome sequences were analyzed from 22 S. 41 Typhi isolates, 20 from stool and 2 from blood samples, all genotype 4.3.1 (H58). Nineteen strains 42 were from four patients also diagnosed with gallstones, of whom, three had typhoid symptoms and 43 continued to shed S. Typhi after treatment. All isolates had point mutations in the quinolone 44 resistance determining region (QRDR) and only sub-lineage 4.3.1.2EA3 encoded multidrug 45 46 resistance genes. There was no variation in antimicrobial resistance patterns among strains from the same patient/household. Non-multidrug resistant (MDR), isolates formed significantly 47 stronger biofilms *in vitro* than the MDR isolates, p < 0.001. A point mutation within the *treB* gene 48 (treB A383T) was observed in strains isolated after clinical resolution from patients living in 75% 49 50 of the households. Missense mutations in Vi capsular polysaccharide genes, tviE P263S was also observed in 18% of the isolates. This study provides insights into the role of typhoid carriage, 51 52 biofilm formation, AMR genes and genetic variations in S. Typhi from asymptomatic carriers.

53 Importance

Although typhoid fever has largely been eliminated in high income countries, it remains a major global public health concern especially among low- and middle-income countries. The bacteria responsible for this infectious disease, *Salmonella* Typhi, has limited ability to replicate outside the human host and human carriers serve as a reservoir of infection. Typhoid is a common infection in parts of sub-Saharan Africa and Asia, and is endemic in our study setting. Our research findings on differences in *S*. Typhi strains causing typhoid fever and carriage will influence public health approaches aimed at reducing carriage and transmission of *S*. Typhi.

61 Key Words: Salmonella Typhi, AMR genes, genetic variation, biofilm, carriage

- 62
- ~ ~
- 63

64 Introduction

Typhoid fever (typhoid), a life-threatening systemic infection caused predominantly by Salmonella 65 enterica subspecies enterica serotype Typhi (S. Typhi), remains a common infection and a public 66 health concern in resource poor-settings in parts of sub-Saharan Africa and Asia (1-3). An 67 estimated 9 million new typhoid fever cases occur each year, of which 2-3% results in death even 68 with adequate antibiotics therapy (4,5). Typical symptoms manifest between 1 and 3 weeks post-69 infection and encompass elevated prolonged fever, headache, malaise, abdominal pain, diarrhea, 70 constipation, hypersplenism and rose-colored spots on the chest (6). S. Typhi is transmitted via the 71 72 fecal-oral route in settings with poor standards of sanitation, low levels of hygiene and inadequate water supply (7,8). Besides inadequate resources, typhoid endemic settings lack a quality public 73 74 health infrastructure (9).

Upon ingestion of contaminated food or water, S. Typhi bacteria that survive the hostile gastric 75 acid rich environment in the stomach, are able to replicate in the new host (9,10). The typhoid 76 bacilli can invade the intestinal mucosa, typically through microfold (M) cells, and establish an 77 78 initially clinically undetectable infection involving significant systemic dissemination and a transient primary bacteremia (9). S. Typhi also reach the gallbladder hematogenously during 79 primary bacteremia or shortly thereafter through infected hepatic bile entering the gallbladder 80 (11,12). S. Typhi bacteria can survive, replicate and evade immune surveillance intracellularly 81 82 within a modified phagosome known as Salmonella-containing vacuole (SCV) (13,14).

Although the majority of patients recover from typhoid fever after an appropriate treatment, some individuals become asymptomatic carriers and shed the infectious typhoid bacilli intermittently in their faeces for an ill-defined period of time after apparent clinical resolution. Since the early 20th century, asymptomatic carriage has been demonstrated to be a source of transmission of typhoid fever, including in the famous case of Mary Mallon (15). Generally, ~2–5% of acute typhoid cases fail to clear the infection fully within one year and develop asymptomatic chronic carriage (16– 18). Approximately 90% of typhoid chronic carriers have gallstones in their gallbladder (19,20).

Persistent colonization of the gallbladder by *S*. Typhi is facilitated by formation of biofilms on the
surface of cholesterol gallstones (19,21). Biofilms are organized three-dimensional multicellular
communities encased in self-produced extracellular polymeric substances (EPS) comprised of
polysaccharides, extracellular DNA [eDNA], proteins and lipids (22). Biofilms account for 80%
of chronic infections in humans, leading to increased rates of hospitalization, high health care

costs, and increased mortality and morbidity rates (23). Bacteria in a biofilm are protected from 95 certain environmental stresses, such as osmotic shifts, oxidative stress, metal toxicity, dehydration, 96 radiation, host immunity, antimicrobial agents, and disinfectants (24). Chronic S. Typhi 97 colonization usually cannot be resolved with antibiotics; gallbladder resection is the only option, 98 although not always effective (21). Biofilm formation leads to continuous shedding and 99 reattachment of planktonic cells, followed by bacteria diffusion in urine and feaces (19,25). Since 100 S. Typhi is a human-restricted pathogen, gallbladder colonization and fecal shedding form a central 101 dogma for further transmission and persistence of typhoid fever. 102

103 In the gallbladder, S. Typhi is exposed to bile, a complex digestive secretion comprised of bile

acids, bilirubin, phospholipids and cholesterol, that exhibit strong antimicrobial properties (26,27).

105 The molecular mechanisms involved in establishing the carrier state are poorly understood;

however S. Typhi is thought to undergo genetic changes within the gallbladder as an adaptive mechanism (21,28,29).

108 Although it is widely accepted that *S*. Typhi carriers contribute to typhoid transmission in endemic

settings, little progress has been made in understanding typhoid carrier state. The current study, we

aimed at identifying the genetic differences in longitudinal clinical S. Typhi isolates from carriers,

in a typhoid endemic setting in Nairobi, Kenya.

112 **RESULTS**

113 Genotype Identification and Clustering Tree

Since the S. Typhi population is highly structured, with dozens of subclades being associated with 114 specific geographical regions and antimicrobial resistance patterns, the genotypes causing 115 asymptomatic carriage in the current study settings were identified. All 22 bacteria isolates were 116 genotype 4.3.1 (S. Typhi Haplotype 58 [H58]). Within this genotype, 11 of the isolates (from 2/4 117 of the households) fell under the lineage 4.3.1.1 (from households A and B) while the remaining 118 119 11 isolates (from households C and D) belong to lineage 4.3.1.2 (Figure 1). Lineage 4.3.1.2 strains were further grouped into two sub-lineages, 4.3.1.2EA2 (4 isolates from the index case in 120 household C) and 4.3.1.2EA3 (7 isolates from an index case in household D). Each patient shed 121 typhoid bacilli belonging to only one lineage/sub-lineage. From household A, isolates (i)-(v) were 122 from and index case while isolate (vi) was from a household contact. Isolates (i) and (ii), household 123 B, were from index case while (iii), (iv) and (v) were from an asymptomatic household contact 124 125 living with the index case. All the S. Typhi strains were isolated from stool samples apart from

two, isolate (i) from household B, and isolate (i) from household D, which were isolated from blood samples. The time of isolation/shedding of each isolate is shown in Table 1. Assembled genomes can be accessed in NCBI database, BioProject ID PRJNA1101423, GenBank accession numbers are shown in the data availability section.

Table 1. Time of isolation/shedding of *S*. Typhi.

131	Household	Category of Study	Time of isolation of S. Typhi isolates (No. of days after the index case was diagnosed with											
132		participant	typhoid fever)											
100			(i)	(ii)	(iii)	(iv)	(v)	(Vi)	(vii)					
133	А	Index case*	0	31	35	39	88	-	-					
134		Household contact	-	-	-	-	-	31	-					
135	В	Index case	0	0	-	-	-	-	-					
136		Household * contact	-	-	29	33	40	-	-					
	С	Index case*	0	22	78	170	-	-	-					
137	D	Index case*	0	21	24	28	35	76	107					
138	*Patients with recruitment w	gallstones in their hile household con	gallblad stacts we	lder. Ind re asyn	dex case	s had sy c and liv	mptom ving wi	is at the th a typ	time of hoid					
139	fever acute cas	se		-	-		-							





141 _____5.00

Figure 1. Clustering tree for *S*. Typhi strains isolated from the study participants living in the different households as generated using the pathogenwatch database and visualized using microreact. Roman numbers indicate specific isolates from the different households (A, B, C and D). Isolates from each household are shown by specific leaf nodes color. Branch tips are color-coded according to the household of isolation. The bar represents branch length scale bar. The tree can be visualized here https://microreact.org/project/s3biz8PE9LDnFayjco22MZ-s-typhi-kenya-2023.

148 Antimicrobial Resistance Genes

Different antimicrobial resistance patterns were observed in the isolated S. Typhi strains. The seven 149 150 isolates belonging to sub-lineage 4.3.1.2EA3 (from Household D) were multidrug resistant, all expressed the following acquired antimicrobial resistance genes; sull, dfrA7, catA1, aph(6)-Id, 151 aph(3'')-Ib, sul2 and bla_{TEM-1}, and a point mutation in the Quinolone Resistance Determining 152 Region (QRDR) of gyrA (gyrA S83Y). Phenotypic susceptibility data showed that these seven 153 isolates were resistant to ampicillin, chloramphenicol, trimethoprim-sulfamethoxazole and 154 nalidixic acid but non-susceptible to ciprofloxacin. The four sub-lineage 4.3.1.2EA2 isolates (S. 155 Typhi strains from Household C) had a gyrB S464F mutation in the QRDR, and all were non-156 susceptible to nalidixic acid and ciprofloxacin according to phenotypic susceptibility results. The 157 third group, lineage 4.3.1.1, had six strains (Household A isolates) with a gyrB S464F mutation, 158 also demonstrating non-susceptibility to nalidixic acid and ciprofloxacin. The other five lineage 159 4.3.1.1 strains (household B isolates) had gyrA S83F mutations in the QRDR, and showed 160 resistance to nalidixic acid and non-susceptibility to ciprofloxacin (Table 2). 161

Antii	microbial Resistanc	ce (AMR)	Salmonella Typhi Isolates N (%)						
Resistance	AMR genes	Antibiotics	Household A	Household B	Household C	Household D			
Pattern	-		(4.3.1.1EA1)	(4.3.1.1EA1)	(4.3.1.2EA2)	(4.3.1.2EA3)			
MDR	sul1, dfrA7, catA1, aph(6)-Id, aph(3")-Ib, sul2, bla _{TEM-1} and point mutation on DNA gyrase sub-unit A (gyrA S83Y)	Resistant to AMP, SXT, CHL and NAL, and reduced susceptibility to CIP	-	-	-	7/7 (100%)			
Non-MDR	Point mutation on DNA gyrase sub-unit A (<i>gyrA</i> S83F)	Resistant to NAL and reduced susceptibility to CIP	-	5/5 (100%)	-	-			
	Point mutation on DNA gyrase sub-unit B (<i>gyrB</i> S464F)	Reduced susceptibility to NAL and CIP	6/6 (100%)	-	4/4 (100%)	-			

Table 2. Antibiotic resistance profiles in isolated *S*. Typhi.

MDR-Multidrug resistant

AMP=Ampicillin, SXT= Sulfamethoxazole-trimethoprim, CHL= Chloramphenicol, NAL= Nalidixic acid, CIP= Ciprofloxacin.

sul1 and sul2 mediates resistance to sulfonamide, bla_{TEM-1} encodes broad-spectrum β -lactamase, $aph(\delta)$ -Id and aph(3'')-Ib confer resistance to streptomycin, dfrA7 confers resistance to trimethoprim, and catA1 confers resistance to chloramphenicol.

163

165 Variant Calling

When comparing genome sequences among the isolates, missense mutations were observed in a 166 167 gene that codes for Trehalose Phosphotransferase System (PTS), trehalose transporter subunit IIBC, treB gene (treB A383T), in 3/7 sub-lineage 4.3.1.2EA3 (Household D) isolates and in tviE 168 gene (tviE P263S), which codes for the gene coding for biosynthesis of Vi polysaccharide 169 biosynthesis protein TviE, in 4/7 isolates in the same group, while 2/7 had both mutations (treB 170 A383T and tviE P263S), (Table 3). A nonsense mutation was observed in 1/7 of the sub-lineage 171 4.3.1.2EA3 isolates in the BCKKFA 12280 locus (E237*) that codes for integrase/transposase 172 family protein. The first follow-up isolate (S. Typhi sub-lineage 4.3.1.2EA2) from the index case 173 living in household C (C ii) had a total of 16 mutations, of which 7 were silent, 8 missense 174 mutations and a deletion in *mutL* gene that codes for DNA mismatch repair endonuclease MutL 175 176 (Table 3 and Supplementary files 2 and 3). The second and third follow-up isolates from the same patient (C iii and C iv) had two silent mutations, one in the *vccC* gene that codes for putative 177 membrane protein YccC and tehA gene that codes for dicarboxylate transporter/tellurite-resistance 178 protein TehA (tehA A124A and vccC R199R mutations respectively) and missense mutations in 179 180 the amiA gene that codes for N-acetylmuramoyl-L-alanine amidase AmiA (amiA V145A mutation). An additional mutation was observed in the LEJNAJ 18700 locus (K124E) that 181 182 encodes for 4-hydroxyphenylacetate permease. The second follow-up isolate from the patient in household C (C iii) had a third missense mutation in the LEJNAJ 10515 locus (D78G) that 183 184 encodes phage baseplate assembly protein V. The follow-up lineage 4.3.1.1 strains, which were isolated from households A and B, also had a few mutations. While no mutation was detected in 185 186 the first follow-up sample from the index case in household A, the second follow-up sample (A iii) had a single nucleotide polymorphism in the crl gene (crl L38P), crl codes for sigma factor-binding 187 188 protein Crl. The third and fourth follow-up S. Typhi isolates from the same patient (A iv and A v) had a silent mutation in the *tnpA* gene (*tnpA* Y41Y) that codes for IS200/IS605 family transposase 189 (Supplementary file 1). From the same household, an S. Typhi strain isolated from a household 190 contact's stool sample (A vi) had a missense mutation in the treB gene (treB A383T). S. Typhi 191 192 bacteria isolated from the stool of the index case living in household B before treatment (isolate 193 ii), had a missense mutation in the waaK gene (waaK P167L) that codes for lipopolysaccharide Nacetylglucosaminyltransferase, compared to the strain from blood sample collected on the same 194 day (Supplementary file 2). 195

Gene/Locus	Seq Change	Household A 4.3.1.1EA1			Household B 4.3.1.1EA1				Household C 4.3.1.2EA2			Household D 4.3.1.2EA3							
		ii	iii	iv	v	vi	ii	iii	iv	V	ii	iii	iv	ii	iii	iv	v	vi	vii
crL	L38P		✓																
treB	A383T					\checkmark					\checkmark			✓			\checkmark		\checkmark
waaK	P167L						\checkmark												
BCKKFA_12280	E237*														\checkmark				
tviE	P263S															\checkmark	\checkmark	\checkmark	\checkmark
LEJNAJ_01195	M224V										\checkmark								
yhhY	R73H										✓								
LEJNAJ_13650	R51W										✓								
yihT	R270C										\checkmark								
rfbP	D196G										\checkmark								
galR	Y98H										\checkmark								
dnaE	E953G										\checkmark								
LEJNAJ 18700	K124E											\checkmark	\checkmark						
amiA	V145A											\checkmark	\checkmark						
LEJNAJ_10515	D78G											\checkmark							
Roman numbers in red represent isolates from household contacts. ✓ indicates isolates with observed missense mutations.																			

- **Table 3**. Missense mutations in *S*. Typhi strains isolated from index cases after apparent clinical
- 197 resolution and from asymptomatic household contacts.

198 Plasmid Identification

S. Typhi genotype 4.3.1 lineages/sub-lineages identified in this study were found to contain 199 plasmids. A total of 22 different plasmids were identified, 12/22 of these had sequences 200 corresponding to known Salmonella species plasmids, 6/22 had sequences corresponding to 201 Escherichia coli plasmids, 2/22 corresponding to Klebsiella pneumoniae plasmids, 1/22 202 corresponding to Enterobacter kobei and 1/22 an Escherichia albertii plasmid (Table 4). Out of 203 the 22 plasmids, 8/22 were detected in all 22 S. Typhi strains. The eight plasmids include 204 Salmonella Infantis strain CFSAN003307 plasmid pCFSAN003307, Salmonella Senftenberg 205 strain NCTC10384 plasmid 4, E. coli strain 13TMH22 plasmid p13TMH22-1, Salmonella enterica 206 subsp. enterica serovar 1,4,[5],12:i:- strain PNCS014880 plasmid p16-6773.2, S. Typhi strain 207 3, Salmonella Typhimurium strain AUSMDU00027951 208 ERL11909 plasmid isolate 209 AUSMDU00027951 plasmid P02, Salmonella Weltevreden plasmid pSH17G0407 and S. Senftenberg strain NCTC10384 plasmid 3. Plasmids with sequences corresponding to E. coli strain 210 88COLEC plasmid p88COLEC-1 and E. coli strain 13P477T plasmid p13P477T-2 were only 211 detected in lineage 4.3.1.2EA2 (Household C) isolates, in 4/4 and 2/4 of the strains respectively. 212 The E. albertii strain 2014C-4356 plasmid unnamed6 was only found in 1/11 of lineage 4.3.1.1 213

- isolates while *Salmonella* Uganda strain CFSAN006208 plasmid pCFSAN006208 1 was detected
- in 1/11 of lineage 4.3.1.1 isolates. Sequences corresponding to five known plasmids, *Salmonella*
- 216 Enteritidis strain 81-1705 plasmid pSE81-1705-3, S. Typhi strain 311189 252186 plasmid
- 217 pHCM1, E. coli NES6 plasmid pN-ES-6-1, K. pneumoniae strain RIVM C018860 plasmid
- pRIVM C018860 2 and K. pneumoniae strain 03108465-40B plasmid pKpQIL, were detected in
- 219 7/7 of sub-group 4.3.1.2EA3 strains but not in the other sub-groups.
- 220 Genes conferring multidrug resistance in S. Typhi were detected in two different plasmids
- identified in sub-group 4.3.1.2EA3 (Household D) strains. The antimicrobial resistance genes *sul1*,
- 222 dfrA, catA1, aph(6)-Id, aph(3")-Ib and sul2 were detected in a plasmid with sequences
- corresponding to *S*. Typhi strain 311189 252186 plasmid pHCM1, while *bla_{TEM-1}* was detected in
- a plasmid with sequences corresponding to *E. coli* NES6 plasmid pN-ES-6-1. None of the plasmids
- in isolates from households A, B and C had identifiable antimicrobial resistance genes.

GenBank Accession Number of isolates per household number of **Origin/Description** with identified plasmid/s plasmids with **HHA** HH C HH B HH D similar sequences NZ CP019203.1 Salmonella Infantis strain CFSAN003307 plasmid 6/6 5/54/47/7pCFSAN003307 NZ LN868946.1 Salmonella Senftenberg strain NCTC10384 plasmid 4 6/6 5/5 4/47/77/7NZ CP019257.1 *Escherichia coli* strain 13TMH22 plasmid p13TMH22-1 5/54/46/6 NZ CP039862.1 Salmonella enterica subsp. enterica serovar 6/6 5/54/47/71,4,[5],12:i:- strain PNCS014880 plasmid p16-6773.2 Salmonella Typhi strain ERL11909 plasmid 3 4/4 NZ LT904874.1 6/6 5/57/7Salmonella Typhimurium strain AUSMDU00027951 NZ OU015330.1 5/57/76/6 4/4isolate AUSMDU00027951 plasmid P02, 4/4 NZ MW405382.1 Salmonella Weltevreden plasmid pSH17G0407 6/6 5/5 7/7NZ LN868945.1 Salmonella Senftenberg strain NCTC10384 plasmid 3 7/76/6 5/54/4CP075030.1 Salmonella Abortusequi strain CFSAN022626 plasmid 5/6 4/54/47/7pCFSAN022626 CP074288.1 Salmonella Uganda strain CFSAN006208 plasmid 1/6_ _ pCFSAN006208 1 Enterobacter kobei strain EB P8 L5 01.19 plasmid NZ CP043512.1 2/61/52/43/7unnamed1 NZ CP026725.1 Escherichia coli strain 266917 2 plasmid 3/6 3/5 2/44/7p266917 2 02 NZ CP022733.1 Escherichia coli strain SA186 plasmid pSA186 4 4/64/52/46/7NZ CP040702.1 Salmonella Weltevreden strain 3 isolate CFSAN047349 3/64/54/47/7plasmid unnamed NZ CP024288.1 Escherichia albertii strain 2014C-4356 plasmid 1/52/7_ unnamed6 NZ CP070907.1 Escherichia coli strain 88COLEC plasmid p88COLEC-4/4 _ NZ CP019275.1 Escherichia coli strain 13P477T plasmid p13P477T-2 2/4NZ CP018654.1 Salmonella Enteritidis strain 81-1705 plasmid pSE81-7/7_ 1705-3 *NZ CP029895.1 Salmonella Typhi strain 311189 252186 plasmid 7/7pHCM1

Table 4. Bacterial plasmids detected in isolated *S*. Typhi strains.

HH=Household

*LC553463.1

NZ CP068928.1

MT809700.1

*Plasmids with antimicrobial resistance genes

227

228

229

7/7

7/7

7/7

Escherichia coli NES6 plasmid pN-ES-6-1

Klebsiella pneumoniae strain RIVM C018860 plasmid

pRIVM C018860 2

Klebsiella pneumoniae strain 03108465-40B plasmid

pKpQIL

Biofilm Formation

We wanted to determine if biofilm-forming ability is correlated with the stage of typhoid 231 232 fever/carriage, antimicrobial resistance or with the presence of plasmids. Biofilms were examined in gallbladder-simulating conditions. There was varying ability to form biofilms under in vitro 233 conditions in the S. Typhi strains tested. All isolates formed weak biofilms in absence of both 234 cholesterol and bile (OD₅₇₀ below 0.3) and significantly strong biofilms in presence of cholesterol 235 and 2.5% human bile (Figure 2A and 2B). Differences in biofilm forming ability was observed 236 across the identified genotype 4.3.1 lineages/sub lineages. The sub-lineage 4.3.1.2EA2 formed the 237 strongest biofilms (OD₅₇₀ slightly above 2.0) while sub-lineage 4.3.1.2EA3 formed relatively weak 238 biofilms (OD₅₇₀ below 0.5) even in the presence of cholesterol and human bile (Figure 2A and 239 2B). The weak biofilm forming isolates, sub-lineage 4.3.1.2EA3, had AMR genes encoded in 2/19 240 of the plasmids identified in this sub-group. Sub-lineages 4.3.1.2EA2 and 4.3.1.1EA1 had fewer 241 identified plasmids, (14 and 15 respectively) (Table 4), None of these plasmids had identifiable 242 AMR genes, but isolates in these subgroups formed significantly stronger biofilms in the presence 243 of both cholesterol and human bile (Figure 2C). However, there was no statistical significance in 244 245 biofilm forming ability in strains isolated during the symptomatic vs. asymptomatic stage in each of the three sub-groups of S. Typhi (Figure 2D). 246





248



250

Figure 2. *Salmonella* Typhi biofilms. (A and B) Quantity of biofilms after growth in presence/absence of cholesterol and/or bile. (C) Biofilm formation by MDR *S*. Typhi strains vs. non-MDR strains. (D) Comparison of biofilms formed by *S*. Typhi strains isolated before treatment vs. after treatment. Error bars represent SEM, ****, P<0.001; **, P<0.05; ^{ns} $P\geq0.5$.

255 Discussion

Although typhoid fever has largely been eliminated in high income countries, it remains a major global public health concern especially among low- and middle-income countries (2). The haplotype 58 (H58), which is associated with antimicrobial resistance has also been reported from other parts of sub-Saharan Africa and Southeast Asia (30,31). In this study, H58 (genotype 4.3.1) was identified as the single genotype shed by four cholelithiasis patients living in a typhoid endemic setting in Nairobi, Kenya. *S.* Typhi H58 is the most dominant genotype in many parts of

Southeast and South Asia as well as in East Africa and has spread globally (32,33). Three H58 east 262 African subgroups (4.3.1.1EA1, 4.3.1.2EA2, 4.3.1.2EA3) previously reported circulating in the 263 264 current study setting by our group (1), were the main lineages/sub-lineages shed by the cholelithiasis patients. The most abundant subgroup was 4.3.1.1EA1 with 11/22 (50%) isolates, 265 originating from individuals living in two different households. In one of these households, an 266 267 acute case shed an S. Typhi belonging to the same sub-group as an asymptomatic household contact who was also diagnosed with gallstones. This suggests possible transmission of the pathogen by 268 the carrier to the household contact (household B). From a different household, a typhoid patient 269 also diagnosed with gallstones continued to shed sub-lineage 4.3.1.2EA2, while in the fourth 270 household, S. Typhi sub-lineage 4.3.1.2EA3 strains were isolated from stool samples collected 271 from an acute case after treatment. Unlike the other two sub-groups, the sub-lineage 4.3.1.2EA3 272 strains had MDR genes, showing resistance to ampicillin, sulfamethoxazole-trimethoprim and 273 chloramphenicol. MDR isolates had more plasmids, 19, compared to the 14 plasmids in non-MDR 274 275 isolates, from 4.3.1.1EA1 and 15 plasmids from 4.3.1.2EA2. The seven sub-lineage 4.3.1.2EA3 strains had the MDR genes detected in identified plasmids. All 22 S. Typhi isolates had point 276 277 mutations in the QRDR, conferring reduced susceptibility to ciprofloxacin, a drug of choice for treating typhoid fever. There was no variation noted in antimicrobial resistance patterns among 278 279 strains isolated from the patients in the same household.

Multidrug resistance genes were not detected in 4.3.1.1EA1 and 4.3.1.2EA2 S. Typhi genomes, 280 281 but the strains belonging to these subgroups formed significantly stronger biofilms as compared to the MDR sub-lineage 4.3.1.2EA3 strains. Biofilms act as physical barrier protecting bacteria from 282 283 killing by antimicrobials including antibiotics. A previous study demonstrated the role of biofilms in protecting Salmonella from ciprofloxacin (34). We hypothesize that the 4.3.1.1EA1 and 284 285 4.3.1.2EA2 sub-lineages form better biofilms to counteract the absence of antimicrobial resistance 286 factors, or conversely, that lineage 4.3.1.2EA3 has lost biofilm-related genes because it possesses more plasmids/genes encoding strong antimicrobial resistance. To the best of our knowledge, this 287 is the first study comparing biofilm forming ability in different S. Typhi lineages. The mechanism 288 289 leading to differences in biofilm formation in isolates from the same genotype will need to be 290 further investigated.

Genetic variations were observed in S. Typhi from asymptomatic carriers, with a *treB* A383T point
 mutation being observed in at least one isolate from each of the four households. The *treB* gene

codes for PTS trehalose transporter subunit IIBC. As seen in Table 3, household B, some of the 293 mutations observed in the first follow-up isolate were not detected in S. Typhi strains isolated 294 295 during the consecutive follow-ups. However, some mutations were observed in more than one strain isolated from the same patient. From the patient shedding sub-lineage 4.3.1.2EA3 strains, 296 the tviE P263S mutation was observed in the fourth isolate and all strains isolated thereafter. This 297 298 suggests that some of the mutations are maintained in the population during the asymptomatic carriage, while others are not. Although no strain was isolated directly from gallbladder in our 299 study, mutations in the tviE gene was also observed in S. Typhi gallbladder genome sequences in 300 a previous study (29). The tviE gene facilitates the polymerization and translocation of the Vi 301 capsule (35). Vi capsular polysaccharide, an antiphagocytic capsule, covers the surface of S. Typhi 302 allowing it to selectively evade phagocytosis by human neutrophils while promoting human 303 304 macrophage phagocytosis (36). This crucial virulence factor in S. Typhi (Vi) also plays a key role in the development of vaccines against typhoid fever (37). However, additional research will be 305 required to understand if this mutation alters the expression of Vi antigen to benefit S. Typhi 306 pathogenesis or chronic carriage. 307

The main limitation in this study is lack of availability of isolates from gallbladder samples from patients shedding *S*. Typhi for comparison with those isolated from stool and blood samples. There were also no *S*. Typhi belonging to other genotypes for comparison purposes.

311 Conclusion

The resistance patterns in S. Typhi did not change during the duration of asymptomatic carriage in 312 313 study participants, but these individuals continued to shed and transmit drug resistant strains of this pathogen. Mutations in S. Typhi were observed to occur during carriage including those in the 314 Vi antigen locus. Sub-lineages analyzed in this study that were not multidrug resistant, showed the 315 ability to form stronger biofilms than the multidrug resistant strains. This study provides some 316 insights into mutations, drug resistance and biofilm formation during typhoid carriage, and this 317 information may be used to influence public health approaches aimed at reducing carriage and 318 transmission of S. Typhi. 319

- 321
- 322
- 323

324 Methods

325 Source of Bacteria strains

The whole genome sequences of 22 S. Typhi strains isolated from blood and stool samples of six 326 patients living in four different households in Mukuru informal settlement, a typhoid endemic area 327 328 in Nairobi, Kenya, were analyzed. Nineteen of these strains were from four patients who were also diagnosed with cholelithiasis, of whom, three had typhoid symptoms and continued to shed S. 329 Typhi after treatment. The presence of gallstones was confirmed through an ultrasound scan, the 330 331 primary imaging modality performed by a radiologist used to evaluate patients suspected of having gallbladder disease. One of the patients with gallstones was asymptomatic but shedding S. Typhi 332 and living in the same household (household B) with an acute typhoid fever case (not diagnosed 333 334 with gallstones). In a different household (household A), a study participant (household contact) 335 not diagnosed with cholelithiasis shed S. Typhi once. The index case from this household was diagnosed with cholelithiasis and continued to shed S. Typhi after treatment with antibiotics. 336 Laboratory methods on isolation and identification of the isolates are as described in our previous 337 publication (38). 338

339 Whole Genome Sequencing

DNA extracted from S. Typhi strains using GenElute[™] Bacterial Genomic DNA Kit (Missouri, 340 United States) was prepared for whole genome sequencing by SeqCoast Genomics using an 341 Illumina DNA Prep tagmentation kit and unique dual indexes. Sequencing was performed on the 342 Illumina NextSeq2000 platform using a 300-cycle flow cell kit to produce 2x150bp paired reads 343 344 as previously described (39). PhiX control, 1-2%, was spiked into the run to support optimal base calling. Read demultiplexing, read trimming, and run analytics were performed using DRAGEN 345 v3.10.12, an on-board analysis software on the NextSeq2000. Raw sequencing data generated 346 during this study are available in the National Center for Biotechnology Information (NCBI) public 347 data, BioProject ID PRJNA1101423. 348

349 Genome Assembly and Annotation

Quality-trimming of the reads was done using Trimmomatic (40). Read error was corrected using SPAdes (41). Short (and long, if available) reads were assembled into contigs using SPAdes (wrapped in Unicycler). Read mapping was done using Bowtie2 and SAMtools (wrapped in Unicycler) (42–44) (<u>https://github.com/rrwick/Porechop</u>). Pilon (wrapped in Unicycler) was used in polishing of each assembly (45). Gene prediction and functional annotation was performed

using BAKTA (46). The annotation pipeline was as follows; prediction of protein-coding genes

- using Prodigal, tRNA identification using tRNAscan-SE (47), tRNA and tmRNA identification
- using Aragorn (48), prediction of rRNA sequences using Infernal and the Rfam database (49),
- 358 CRISPR prediction using PILER-CR (50), antimicrobial resistance gene identification using
- AMRFinderPlus (51), prediction of signal peptides using DeepSig (52), prediction of transposases
- using ISFinder (53) and computation of codon usage biases for each amino acid.

361 Genotype Identification and Bacteria Clustering

- Identification and clustering of *S*. Typhi genotypes was performed using Pathogenwatch (https://pathogen.watch/), a web-based platform with several different components (54,55). The platform provides compatibility with *S*. Typhi typing information for MLST (56), in silico serotyping (SISTR) (57), and a SNP genotyping scheme (GenoTyphi) (55). *S*. Typhi Assemblies (in fasta format) were uploaded to the platform <u>https://pathogen.watch/upload/fasta</u> for the
- 367 analysis.

368 Antimicrobial Susceptibility Testing

- Antimicrobial susceptibility testing was performed using the disk diffusion technique for all antimicrobials commonly used in Kenya for typhoid fever treatment including ampicillin (10 μ g), tetracycline (30 μ g), co-trimoxazole (25 μ g), chloramphenicol (30 μ g), amoxicillin-clavulanate (20/10 μ g), cefpodoxime 30 μ g, ceftazidime (30 μ g), ceftriaxone (30 μ g), cefotaxime (30 μ g), azithromycin (15 μ g), ciprofloxacin (5 μ g), nalidixic acid (10 μ g), kanamycin (30 μ g) and
- 374 gentamic $(10 \mu g)$. The diameter of the zone of inhibition was measured after 18-24 hours and
- 375 results were interpreted according the Clinical and Laboratory Standards Institute (CLSI)
- 376 guidelines for *Salmonella* (CLSI 2023).

377 Screening of Antimicrobial Resistance Genes

- 378 NCBI Antimicrobial Resistance Gene Finder Plus (AMRFinderPlus)
 379 (<u>https://github.com/ncbi/amr/wiki</u>), was used to identify acquired antimicrobial resistance genes
 380 and known resistance-associated point mutations in *S*. Typhi assembled nucleotide sequences (51).
- 381 The results were compared with phenotypic susceptibility data.

382 Variant Calling

To identify genetic variations between the longitudinal clinical isolates, *S*. Typhi strains isolated before each typhoid index case was treated with antibiotics were used as the reference genome, and were compared with those isolated after treatment (follow-up isolates), and/or those isolated

- from household contacts using breseq (58). The variant calling pipeline was as follows; quality-
- filtering of raw reads using Trimmomatic (40), mapping of reads against a reference genome (first
- 388 strain isolated from the index case), analysis of possible mutations based on mapping data,
- identification of mutations and graphical and tabular summaries of mutation profile across samples
- - 390 (42).

391 Plasmid Identification

To identify plasmids in the isolated *S*. Typhi strains, a plasmid detection tool PLASMe was used (<u>https://github.com/HubertTang/PLASMe</u>). The tool uses the alignment component in PLASMe to identify closely related plasmids while diverged plasmids are predicted using order-specific Transformer models (59).

396 In *Vitro* Biofilm Formation Assays

397 Because of the importance of biofilm formation on gallstones in chronic carriage (17,19) the biofilm forming ability of all the 22 human S. Typhi isolates were tested under gallbladder 398 simulating conditions. S. Typhi biofilms were grown on non-treated polystyrene 96-well plates 399 (Corning, Kennebunkport, ME). To simulate growth conditions on gallstones, wells in two plates 400 401 were pre-coated with cholesterol by adding a solution of 5 mg/mL in 1:1 isopropanol:ethanol and air-dried overnight. A pure colony of S. Typhi on an XLD agar plate was cultured in Tryptone Soy 402 403 Broth (TSB). Overnight (O/N) cultures in broth were normalized to $OD_{600}=0.8$, diluted 1:2500 in TSB or TSB containing 2.5% human bile, and 100 µL/well were dispensed into the plates. The 404 405 plates were incubated at 25°C in a Fisherbrand[™] nutating mixer (Thermo Fisher Scientific; Hampton, NH) at 24 rpm for 96 hours. Media (TSB or TSB containing bile) was changed after 406 407 every 24 hours for consistent S. Typhi biofilm growth. Plates were emptied on the fourth day and washed twice before heat fixing at 60°C for 1 hour. The biofilms were stained using a crystal violet 408 409 solution and acetic acid (33%) used to elute crystal violet before reading the OD₅₇₀. GraphPad prism 9.5 was used to analyze the biofilm formation results. One way Analysis 410

411 of variance (ANOVA) was used to test level of significance in biofilm formation between the 412 different *S*. Typhi sub-lineages and in different conditions, i.e., biofilms in absence of cholesterol 413 and bile, in cholesterol coated plates in absence of bile, and in presence of cholesterol and bile. 414 Student's t-test was used to test level of significance in biofilm formation in strains isolated before 415 treatment vs last strains shed by the patient, P-values less than 0.05 (P<0.05) were considered</p>

416 significant.

417 Data Availability

- 418 The whole genome sequences from all the 22 S. Typhi isolates were deposited to the National
- 419 Center for Biotechnology Information (NCBI), GenBank accession numbers are shown in the table
- 420 below (Table 5).
- 421 **Table 5.** GenBank accession numbers of analyzed *S*. Typhi sequences

Isolate	BioSample	Whole Genome	URL
No.	Accession	Sequence Accession	
Ai	SAMN40992305	JBCHCG000000000	https://www.ncbi.nlm.nih.gov/nuccore/JBCHCG000000000
Aii	SAMN40992306	JBCHCF000000000	https://www.ncbi.nlm.nih.gov/nuccore/JBCHCF000000000
Aiii	SAMN40992307	JBCHCE000000000	https://www.ncbi.nlm.nih.gov/nuccore/2725100554
Aiv	SAMN40992308	JBCHCD00000000	https://www.ncbi.nlm.nih.gov/nuccore/JBCHCD000000000
Av	SAMN40992309	JBCHCC000000000	https://www.ncbi.nlm.nih.gov/nuccore/JBCHCC000000000
Avi	SAMN40992310	JBCHCB000000000	https://www.ncbi.nlm.nih.gov/nuccore/JBCHCB000000000
Bi	SAMN40992311	JBCHCA000000000	https://www.ncbi.nlm.nih.gov/nuccore/JBCHCA000000000
Bii	SAMN40992312	JBCHBZ00000000	https://www.ncbi.nlm.nih.gov/nuccore/JBCHBZ000000000
Biii	SAMN40992313	JBCHBY000000000	https://www.ncbi.nlm.nih.gov/nuccore/JBCHBY000000000
Biv	SAMN40992314	JBCHBX000000000	https://www.ncbi.nlm.nih.gov/nuccore/JBCHBX000000000
Bv	SAMN40992315	JBCHBW000000000	https://www.ncbi.nlm.nih.gov/nuccore/JBCHBW000000000
Ci	SAMN40992316	JBCHBV000000000	https://www.ncbi.nlm.nih.gov/nuccore/JBCHBV000000000
Cii	SAMN40992317	JBCHBU000000000	https://www.ncbi.nlm.nih.gov/nuccore/JBCHBU000000000
Ciii	SAMN40992318	JBCHBT000000000	https://www.ncbi.nlm.nih.gov/nuccore/JBCHBU000000000
Civ	SAMN40992319	JBCHBS000000000	https://www.ncbi.nlm.nih.gov/nuccore/JBCHBS000000000
Di	SAMN40992320	JBCHBR000000000	https://www.ncbi.nlm.nih.gov/nuccore/JBCHBR000000000
Dii	SAMN40992321	JBCHBQ000000000	https://www.ncbi.nlm.nih.gov/nuccore/JBCHBQ000000000
Diii	SAMN40992322	JBCHBP000000000	https://www.ncbi.nlm.nih.gov/nuccore/JBCHBP000000000
Div	SAMN40992323	JBCHBO000000000	https://www.ncbi.nlm.nih.gov/nuccore/JBCHBO000000000
Dv	SAMN40992324	JBCHBN000000000	https://www.ncbi.nlm.nih.gov/nuccore/JBCHBN000000000
Dvi	SAMN40992325	JBCHBM000000000	https://www.ncbi.nlm.nih.gov/nuccore/JBCHBM000000000
Dvii	SAMN40992326	JBCHBL000000000	https://www.ncbi.nlm.nih.gov/nuccore/JBCHBL000000000

422

423 Acknowledgements

- 424 This research was financially supported by the National Institute of Health (NIH) National Institute
- 425 of Allergy and infectious Diseases (Grants: R01 AI099525 and R01 AI116917).

426 **Conflict of Interest**

427 The authors declare that they have no competing interests.

429

References

- Kariuki S, Dyson ZA, Mbae C, Ngetich R, Kavai SM, Wairimu C, Anyona S, Gitau M,
 Onsare RS, Ongandi B. 2021. Multiple introductions of multidrug-resistant typhoid
 associated with acute infection and asymptomatic carriage, Kenya. *Elife*10:e67852.
- Kim CL, Cruz Espinoza LM, Vannice KS, Tadesse BT, Owusu-Dabo E, Rakotozandrindrainy
 R, Jani IV, Teferei M, Bassiahi Soura A, Lunguya O. 2022. The burden of typhoid fever in
 sub-Saharan Africa: a perspective. *Res Rep Trop Med*1–9.
- 3. Stanaway JD, Reiner RC, Blacker BF, Goldberg EM, Khalil IA, Troeger CE, Andrew JR,
 Bhutta JR, Crump JA, Im J. 2019. The global burden of typhoid and paratyphoid fevers: a
 systematic analysis for the Global Burden of Disease Study 2017. *Lancet Infect Dis*19(4):369–81.
- 4. Pieters Z, Saad NJ, Antillón M, Pitzer VE, Bilcke J. 2018. Case fatality rate of enteric fever
 in endemic countries: a systematic review and meta-analysis. *Clin Infect Dis*67(4):628–38.
- 5. Typhoid [Internet]. [cited 2024 May 30]. Available from: https://www.who.int/news-room/fact-sheets/detail/typhoid
- 444 6. World Health Organization. Typhoid vaccines: WHO position paper, March 2018–
 445 Recommendations. 2019. *Vaccine*37(2):214–6. Accessed May 2024.
- 446 7. Crump JA. 2019. Progress in typhoid fever epidemiology. *Clin Infect*447 *Dis*68(Supplement_1):S4–9.
- 8. Parry CM, Thuy CT, Dongol S, Karkey A, Vinh H, Chinh NT, Duy PT, Thieu Nga TV,
 Campbell JI, Van Minh Hoang N. 2010. Suitable disk antimicrobial susceptibility
 breakpoints defining Salmonella enterica serovar Typhi isolates with reduced susceptibility
 to fluoroquinolones. *Antimicrob Agents Chemother*54(12):5201–8.
- 9. Dougan G, Baker S. 2014. Salmonella enterica serovar Typhi and the pathogenesis of typhoid fever. *Annu Rev Microbiol*68:317–36.
- 454 10. Ahirwar SK, Pratap CB, Patel SK, Shukla VK, Singh IG, Mishra OP, Kumar K, Singh TB,
 455 Nath G. 2014. Acid exposure induces multiplication of Salmonella enterica serovar Typhi. J
 456 *Clin Microbiol*52(12):4330–3.
- 457 11. Gaines S, Sprinz H, Tully JG, Tigertt WD. 1968. Studies on infection and immunity in
 458 experimental typhoid fever: VII. The distribution of Salmonella typhi in chimpanzee tissue
 459 following oral challenge, and the relationship between the numbers of bacilli and
 460 morphologic lesions. *J Infect Dis*293–306.
- 461 12. Hoffman SA, Sikorski MJ, Levine MM. 2023. Chronic Salmonella Typhi carriage at sites
 462 other than the gallbladder. *PLoS Negl Trop Dis*17(3):e0011168.
- 13. Dougan G, John V, Palmer S, Mastroeni P. 2011. Immunity to salmonellosis. *Immunol Rev*240(1):196–210.
- 465 14. Steele-Mortimer O. 2008. The Salmonella-containing vacuole—moving with the times. *Curr* 466 *Opin Microbiol*11(1):38–45.
- 467 15. Marineli F, Tsoucalas G, Karamanou M, Androutsos G. 2013. Mary Mallon (1869-1938) and
 468 the history of typhoid fever. *Ann Gastroenterol Q Publ Hell Soc Gastroenterol*26(2):132.
- 16. Dongol S, Thompson CN, Clare S, Nga TVT, Duy PT, Karkey A, Arjyal A, Koirala S, Khatri
 NS, Maskey P. 2012. The microbiological and clinical characteristics of invasive Salmonella
 in gallbladders from cholecystectomy patients in Kathmandu, Nepal.
 - 19

- 17. Gunn JS, Marshall JM, Baker S, Dongol S, Charles RC, Ryan ET. 2014. Salmonella chronic 472 carriage: epidemiology, diagnosis, and gallbladder persistence. Trends Microbiol22(11):648-473 55.
- 474
- 475 18. Parry CM, Hien TT, Dougan G, White NJ, Farrar JJ. 2002. Typhoid fever.
- 19. Crawford RW, Rosales-Reves R, Ramirez-Aguilar M de la L, Chapa-Azuela O, Alpuche-476 Aranda C, Gunn JS. 2010. Gallstones play a significant role in Salmonella spp. gallbladder 477 colonization and carriage. Proc Natl Acad Sci107(9):4353-8. 478
- 479 20. Lovane L, Martínez MJ, Massora S, Mandomando I, Ussene E, Jordao D, Castillo P, Imail 480 MR, Lorenzoni C, Carrilho C. 2016. Carriage prevalence of Salmonella enterica serotype Typhi in gallbladders of adult autopsy cases from Mozambique. J Infect Dev 481 Ctries10(04):410-2. 482
- 21. Gonzalez-Escobedo G, Marshall JM, Gunn JS. 2011. Chronic and acute infection of the gall 483 bladder by Salmonella Typhi: understanding the carrier state. Nat Rev Microbiol9(1):9-14. 484
- 22. Flemming HC, Wingender J. 2010. The biofilm matrix. Nat Rev Microbiol8(9):623-33. 485
- 23. Römling U, Balsalobre C. 2012. Biofilm infections, their resilience to therapy and innovative 486 treatment strategies. J Intern Med272(6):541-61. 487
- 488 24. Steenackers H, Hermans K, Vanderleyden J, De Keersmaecker SC. 2012. Salmonella 489 biofilms: an overview on occurrence, structure, regulation and eradication. Food Res 490 Int.45(2):502-31.
- 491 25. Gonzalez-Escobedo G, Gunn JS. 2013. Identification of Salmonella enterica serovar 492 Typhimurium genes regulated during biofilm formation on cholesterol gallstone surfaces. Infect Immun81(10):3770-80. 493
- 494 26. An C, Chon H, Ku W, Eom S, Seok M, Kim S, Lee J, Kim D, Lee S, Koo H. 2022. Bile acids: Major regulator of the gut microbiome. *Microorganisms*10(9):1792. 495
- 27. Staley C, Weingarden AR, Khoruts A, Sadowsky MJ. 2017. Interaction of gut microbiota 496 497 with bile acid metabolism and its influence on disease states. Appl Microbiol Biotechnol101:47-64. 498
- 28. Neiger MR, González JF, Gonzalez-Escobedo G, Kuck H, White P, Gunn JS. 2019. 499 Pathoadaptive alteration of Salmonella biofilm formation in response to the gallbladder 500 environment. J Bacteriol201(14):10-1128. 501
- 502 29. Thanh Duy P, Thieu NTV, Nguyen Thi Nguyen T, Ngoc Dan Thanh H, Dongol S, Karkey A, Carey M, Basnyat B, Dougan G, Rabaa MA. 2020. Gallbladder carriage generates genetic 503 504 variation and genome degradation in Salmonella Typhi. *PLoS Pathog*16(10):e1008998.
- 30. Maes M, Dyson ZA, Higginson EE, Fernandez A, Araya P, Tennant SM, Baker S, Lagos R, 505 Levine MM, Hormazabal JC. 2020. Multiple introductions of salmonella enterica serovar 506 typhi H58 with reduced fluoroquinolone susceptibility into Chile. Emerg Infect 507 Dis26(11):2736. 508
- 31. Pragasam AK, Pickard D, Wong V, Dougan G, Kang G, Thompson A, John J, Balaji V, 509 510 Mutreja A. 2020. Phylogenetic analysis indicates a longer term presence of the globally distributed H58 haplotype of Salmonella Typhi in Southern India. Clin Infect Dis71(8):1856-511 512 63.
- 513 32. Park SE, Pham DT, Boinett C, Wong VK, Pak GD, Panzner U, Espinoza LMC, von 514 Kalckreuth V, Im J, Schütt-Gerowitt H. 2018. The phylogeography and incidence of multidrug resistant typhoid fever in sub-Saharan Africa. Nat Commun9(1):5094. 515
- 516 33. Wong VK, Baker S, Pickard DJ, Parkhill J, Page AJ, Feasey NA, Kingsley RA, Thomson
- NR, Keane JA, Weill F. 2015. Phylogeographical analysis of the dominant multidrug-517

resistant H58 clade of Salmonella Typhi identifies inter-and intracontinental transmission 518 events. Nat Genet47(6):632-9. 519 34. González JF, Alberts H, Lee J, Doolittle L, Gunn JS. 2018. Biofilm formation protects 520 521 Salmonella from the antibiotic ciprofloxacin in vitro and in vivo in the mouse model of chronic carriage. Sci Rep8(1):222. 522 35. Virlogeux I, Waxin H, Ecobichon C, Popoff MY. 1995. Role of the viaB locus in synthesis, 523 transport and expression of Salmonella typhi Vi antigen. Microbiology141(12):3039-47. 524 525 36. Zhang LF, Lepenies B, Nakamae S, Young BM, Santos RL, Raffatellu M, Cobb BA, Hiyoshi H, Bäumler AJ. 2022. The vi capsular polysaccharide of Salmonella typhi promotes 526 macrophage phagocytosis by binding the human c-type lectin DC-SIGN. Mbio13(6):e02733-527 528 22. 37. Hu X, Chen Z, Xiong K, Wang J, Rao X, Cong Y. 2017. Vi capsular polysaccharide: 529 Synthesis, virulence, and application. Crit Rev Microbiol43(4):440-52. 530 38. Muturi P, Wachira P, Wagacha M, Mbae C, Kavai S, Muhammed M, Gunn JS, Kariuki S. 531 2024. Fecal Shedding, Antimicrobial Resistance and In Vitro Biofilm formation on 532 Simulated Gallstones by Salmonella Typhi Isolated from Typhoid Cases and Asymptomatic 533 534 Carriers in Nairobi, Kenya. Int J Clin Microbiol1(2):23-36. 39. Grant NA, Sontz JT, Waters CM. 2023. Deployment of a Vibrio cholerae ordered transposon 535 mutant library in a quorum-competent genetic background. bioRxiv 536 537 40. Bolger AM, Lohse M, Usadel B. 2014. Trimmomatic: a flexible trimmer for Illumina sequence data. *Bioinformatics* 30(15):2114–20. 538 41. Bankevich A, Nurk S, Antipov D, Gurevich AA, Dvorkin M, Kulikov AS, Lesin VM, 539 540 Nikolenko SI, Pham S, Prjibelski AD. 2012. SPAdes: a new genome assembly algorithm and 541 its applications to single-cell sequencing. J Comput Biol19(5):455-77. 42. Langmead B, Salzberg SL. 2012. Fast gapped-read alignment with Bowtie 2. Nat 542 543 *Methods*9(4):357–9. 43. Li H, Handsaker B, Wysoker A, Fennell T, Ruan J, Homer N, Marth G, Abecasis G, Durbinn 544 545 R. 2009. The sequence alignment/map format and SAMtools. *bioinformatics*25(16):2078–9. 44. Wick RR, Judd LM, Gorrie CL, Holt KE. 2017. Unicycler: resolving bacterial genome 546 assemblies from short and long sequencing reads. PLoS Comput Biol13(6):e1005595. 547 45. Walker BJ, Abeel T, Shea T, Priest M, Abouelliel A, Sakthikumar S, Cuomo CA, Zeng Q, 548 Wortman J, Young SK .2014. Pilon: an integrated tool for comprehensive microbial variant 549 550 detection and genome assembly improvement. PloS One9(11):e112963. 46. Schwengers O, Jelonek L, Dieckmann MA, Beyvers S, Blom J, Goesmann A. 2021. Bakta: 551 rapid and standardized annotation of bacterial genomes via alignment-free sequence 552 553 identification. Microb Genomics7(11):000685. 554 47. Chan PP, Lowe TM. 2019. tRNAscan-SE: searching for tRNA genes in genomic sequences. Springer.. 555 556 48. Laslett D, Canback B. 2004. ARAGORN, a program to detect tRNA genes and tmRNA genes in nucleotide sequences. Nucleic Acids Res32(1):11-6. 557 49. Nawrocki EP, Eddy SR. 2013. Infernal 1.1: 100-fold faster RNA homology searches. 558 559 Bioinformatics29(22):2933-5. 560 50. Edgar RC. 2007. PILER-CR: fast and accurate identification of CRISPR repeats. BMC Bioinformatics8:1–6. 561 562 51. Feldgarden M, Brover V, Gonzalez-Escalona N, Frye J, Haendiges J, Haft D, Hoffmann M, Pettengill JB, Prasad AB, Tillman GE. 2021. AMRFinderPlus and the Reference Gene 563

- Catalog facilitate examination of the genomic links among antimicrobial resistance, stress
 response, and virulence. *Sci Rep*11: 12728.
- 566 52. Savojardo C, Martelli PL, Fariselli P, Casadio R. 2018. DeepSig: deep learning improves
 567 signal peptide detection in proteins. *Bioinformatics* 34(10):1690–6.
- 53. Siguier P, Pérochon J, Lestrade L, Mahillon J, Chandler M. 2006. ISfinder: the reference
 centre for bacterial insertion sequences. *Nucleic Acids Res*34(suppl_1):D32–6.
- 570 54. Argimón S, Yeats CA, Goater RJ, Abudahab K, Taylor B, Underwood A, Sánchez-Busó L,
- Wong VK, Dyson ZA, Nair S. 2021. A global resource for genomic predictions of
 antimicrobial resistance and surveillance of Salmonella Typhi at pathogenwatch. *Nat Commun*12(1):2879.
- 55. Wong VK, Baker S, Connor TR, Pickard D, Page AJ, Dave J, Murphy N, Holliman R, Sefton
 A, Millar M. 2016. An extended genotyping framework for Salmonella enterica serovar
 Typhi, the cause of human typhoid. *Nat Commun*7(1):12827.
- 577 56. Sharma P, Dahiya S, Balaji V, Kanga A, Panda P, Das R, Dhanraju A, Mendiratta DK, Sood
- 578 S, Das BK. 2016. Typhoidal salmonellae: Use of multi-locus sequence typing to determine 579 population structure. *PLoS One*11(9):e0162530.
- 57. Yoshida CE, Kruczkiewicz P, Laing CR, Lingohr EJ, Gannon VP, Nash JH, Taboada EN.
 2016. The Salmonella in silico typing resource (SISTR): an open web-accessible tool for
- rapidly typing and subtyping draft Salmonella genome assemblies. *PloS One*11(1):e0147101.
- 583 58. Deatherage DE, Barrick JE. 2014. Identification of mutations in laboratory-evolved microbes
 584 from next-generation sequencing data using breseq. *Eng Anal Multicell Syst Methods*585 *Protoc*165–88.
- 586 59. Tang X, Shang J, Ji Y, Sun Y. 2023. PLASMe: a tool to identify PLASMid contigs from
 short-read assemblies using transformer. *Nucleic Acids Res*51(15):e83–e83.
- 588